3 ms·
$90 per pill and about $100k per year per patient, life long? I should do some math to understand how many of those patients a country is able to sustain. Priva
by pmontra 11y ago
$90 per pill and about $100k per year per patient, life long? I should do some math to understand how many of those patients a country is able to sustain. Private insurances or welfare don't make much difference, somebody has to pay all that money and few people make 100k per year plus what they need to live.
- Retric 11y agoThe patent is only for a relatively short period and Cancer is generally not a contagious disease. So, really it's 90$ per pill now, and 10cents a pill for the rest of time. PS: Don't forget, the company was sold for 21 billion which is chump change for the world.
- gwern 11y agoThe quick estimate is that US per capita GDP is ~$50k and the population is ~320m. So you can immediately upper bound it at half the population or 160m patients (two people earn <100k, which pays for <1 person's treatment). This is why health economics tends to use much lower amounts like $50k per QALY. I don't know if the UK's NHS has approved Ibrutinib, but if they have, they must've gotten a big price break from Pharmacyclics because $100k is way above any price they would approve.
- hawkice 11y agoThe NHS seems to have approved it at ~17% discount (but may be towards a higher risk group because it is only available as a first-line medication if you have a chromosomal anomaly -- I am not sure of the relevance of this but it seems it's not the preferred treatment in other cases): http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5810 http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp... That lists the per-pill price as about 51 gbp or 75 usd instead of 90 usd.
- rbanffy 11y ago> $100k per year per patient, life long? It doesn't cure anything. It just slows down the cancer for some time, so, "life long" isn't that long. It's kind of a race of patient against patent.